Effects of ppis and an H2 blocker on the antiplatelet function of clopidogrel in Japanese patients under dual antiplatelet therapy

Journal of Atherosclerosis and Thrombosis

Volumn 19, Issue 6, 2012, Pages 559-569

  Yamane, Keiichiro ^a   Kato, Yoshihiro ^a   Tazaki, Junichi ^a   Tada, Tomohisa ^a   Makiyama, Takeru ^a   Imai, Masao ^a   Jinnai, Toshikazu ^a,b   Ikeda, Tomoyuki ^a,c   Shirakawa, Ryutaro ^a,d   Kimura, Takeshi ^a   Horiuchi, Hisanori ^a,d  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c Hikone Municipal Hospital   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

Antiplatelet therapy; Clopidogrel; Famotidine; Omeprazole; Rabeprazole

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; RABEPRAZOLE; RAPAMYCIN;

ADD ON THERAPY; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOASSAY; ISCHEMIC HEART DISEASE; JAPAN; JAPANESE; MALE; OPTICAL AGGREGOMETER; OPTICS; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; STENT THROMBOSIS; STIMULUS; THROMBOCYTE AGGREGATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; ASPIRIN; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; OMEPRAZOLE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 84863548786     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.11601     Document Type: Article

References (30)

1. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents. JAMA, 2005; 293: 2126-2130
2. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE: A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med, 1998; 339: 1665-1671
3. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet, 2001; 358: 527-533
4. Savi P, Herbert JM: Clopidogrel and ticlopidine: P2y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost, 2005; 31: 174-183
5. Horiuchi H: Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems. Ann Med, 2006; 38: 162-172
6. Ueno M, Kodali M, Tello-Montoliu A, Angiolillo DJ: Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb, 2011; 18: 431-442
7. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 2009; 302: 849-857
8. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med, 2009; 360: 354-362
9. Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T: Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in japan. Circ J, 2009; 73: 1498-1503
10. Umemura K, Furuta T, Kondo K: The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost, 2008; 6: 1439-1441
11. Alvan G, Bechtel P, Iselius L, Gundert-Remy U: Hydroxylation polymorphisms of debrisoquine and mephenytoin in european populations. Eur J Clin Pharmacol, 1990; 39: 533-537
12. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM: Metoprolol and mephenytoin oxidation polymorphisms in far eastern oriental subjects: Japanese versus mainland chinese. Clin Pharmacol Ther, 1989; 46: 198-207
13. Kang MK, Jeong YH, Yoon SE, Koh JS, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY: Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous coronary intervention. J Atheroscler Thromb, 2010; 17: 1122-1131
14. Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and nsaid use: A report of the american college of cardiology foundation task force on clinical expert consensus documents. Circulation, 2008; 118: 1894-1909
15. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities. Drug Metab Dispos, 2004; 32: 821-827
16. Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, doubleblind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol, 2008; 51: 256-260
17. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS: Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 2009; 301: 937-944
18. Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, Flockhart DA: Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel medco outcomes study. Circulation, 2008; 118: S815
19. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF: ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and nsaid use: A report of the American college of cardiology foundation task force on expert consensus documents. Circulation, 2010; 122: 2619-2633
20. Taha AS, McCloskey C, Prasad R, Bezlyak V: Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A phase iii, randomised, double-blind, placebo-controlled trial. Lancet, 2009; 374: 119-125
21. Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC: Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology, 2010; 138: 82-88
22. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K: Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation, 2009; 119: 987-995
23. Born GV, Hume M: Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature, 1967; 215: 1027-1029
24. Tabuchi A, Taniguchi R, Takahashi K, Kondo H, Kawato M, Morimoto T, Kimura T, Kita T, Horiuchi H: Action of aspirin on whole blood-aggregation evaluated by the screen filtration pressure method. Circ J, 2008; 72: 420-426
25. Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, Ikeda T, Yamamoto H, Akao M, Furukawa Y, Shizuta S, Toma M, Tamura T, Saito N, Doi T, Ozasa N, Jinnai T, Takahashi K, Watanabe H, Yoshikawa Y, Nishimoto N, Ouchi C, Morimoto T, Kita T, Kimura T: Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J, 2009; 73: 336-342
26. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schomig A, Kastrati A, von Beckerath N: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost, 2009; 101: 714-719
27. Furuta T, Iwaki T, Umemura K: Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol, 2010; 70: 383-392
28. Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, Kawahara Y, Okamura N, Kirita S, Kasuga M, Okumura K: Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull, 2003; 26: 386-390
29. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomized trials. Lancet, 2009; 374: 989-997
30. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP: Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med, 2010; 363: 1909-1917